A recently described putative tumor suppressor gene, the cyclin-dependent kinase 4 inhibitor (~161, has been shown to be altered by deletions and/or point mutations in various human cancers. To assess the incidence and clinico-biologic correlations of p16 homozygous deletion in hemopoietic tumors, we studied a panel of 244 DNA samples representative of distinct acute (99 cases) and chronic (57 cases) leukemia subtypes, myelodysplastic (22 cases) and myeloproliferative (15 cases) syndromes, and lymphomas (51 cases). A 361-bp probe complementary to the p16 exon 2 gene sequences was generated by polymerase chain reaction and used in Southern blot hybridization against these tumor DNAs. Homozygous deletions of p16 (p16 -I-) were detected in 10 of 58 (17%) cases of acute lymphoblastic leukemia (ALL) of N EUKARYOTES, various proteins with positive or negative regulatory activity participate in the control of the cell cycle.' The cyclin-dependent kinase 4 (CDK4) inhibitor gene encodes a 16-kD protein (p16) with function of negative regulation of cell cycle progression.* Recently, deletions and mutations in the p16 gene have been reported in a variety of human cancers, including leukemia, suggesting that p16 is a novel tumor-suppressor gene.3'7 Thus, like other previously characterized anti-oncogenes fie, p53, RE, and WTl),'"' the p16 gene would be a potential target of lesions leading to inactivation (loss of function) of its encoded protein, and these alterations might represent important steps during tumorigenesis.
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Whereas preliminary studies reported p16 deletions and mutations in a striking proportion of tumor cell l i n e~,~.~ other investigators have found that such alterations are much less frequent in primary As concerns hematopoietic neoplasia, scarce information is available on the incidence and tumor subtype distribution of p16 abn~rmalities.~ In addition, nothing is known about their clinical significance.
We analyzed the frequency of p16 homozygous deletion in a wide panel of pathologic DNAs obtained from patients with various types of leukemia, lymphoma, and myelodysplastic syndromes.
Our results indicate that p16 homozygous deletions are found in a significant fraction of acute lymphoblastic leukemias (ALLs). These cases are characterized by other clinically relevant genetic alterations, aggressive disease features, and poor clinical outcome.
I

MATERIALS AND METHODS
DNA samples. Two hundred forty-four samples stored in our DNA bank were used for this study. This panel included various types of hematopoietic diseases diagnosed and treated at a single institution (Hematology, Department of Human Biopathology of the University "La Sapienza" of Rome) during the period from 1991 to 1994. As shown in Table I ases; size-fractioned by electrophoresis through 0.8% agarose gels; denatured; and transferred to nitrocellulose membranes. These DNAs were prehybridized for 2 to 4 hours at 42°C in a solution containing 50% deionized formamide. 5X Denhardt's solution, and 1 0 0 pglmL denatured salmon sperm D N A and then hybridized at 42°C for 16 to 18 hours in the same solution with the denatured p16 exon 2 probe previously labeled with "P by the random priming technique. Filters were washed at room temperature for 10 minutes in 0.2X SSC/0.I% sodium dodecyl sulfate (SDS) and at 50°C for 15 to 20 minutes in the same solution. The filters were then exposed for 2 to 8 days at -80°C for autoradiography using intensifying screens.
The 3' M-BCR and B859 probes, which explore the major B breakpoint cluster region at 22ql I and the A L L -l breakpoint region at chromosome I lq23. respectively, were also used to study the configuration o f these genes in A L L and CML. In addition to the detection o f rearrangements at these loci, these probes served as controls for the assessment o f the D N A amount present in the filters.
The characteristics o f the 3' M-BCR and B859 probes are reported elsewhere,'"'"
Single-strand conformation polymorphism (SSCP) analysis of p16 exons I and 2. PCR amplification o f p16 exon 2 was performed using the same primers reported above. Amplification of exon I was performed according to a recently published procedure.'' For SSCP analysis, PCR products were heat-denatured. loaded into a neutral 6 8 polyacrylamide gel containing 10% (vollvol) glycerol, and detected by silver nitrate staining.
Estimation of the leukemic cell mass in ALL (risk factor) and statistical ana/ysis. The leukemic cell mass estimate (risk factor 
RESULTS
Nucleotide sequence of the cloned 360-bp probe generated by PCR using pl6-specific oligomers confirmed that this fragment corresponded to the p16 exon 2 (data not shown). Tumor DNAs showing at Southern analysis hybridizing bands with various control probes and no hybridization signal after probing with p16 were considered to be homozygously deleted at the p16 locus (Fig 1) .
Homozvgous loss of p16 in diferent hemntopoietic tumors. Ten of 244 cases studied were found to be homozygously deleted at the p16 locus (Table l). All of these cases SSCP analysis of p16 exons I and 2. Forty ALL cases. including 6 of the 10 found deleted at Southern blot, and 12 of the 43 NHL cases were also analyzed by PCR-SSCP of p16 exons I and 2. In none of these cases were point muta- tions detected. Of the 6 deleted ALL cases. 4 did not show PCR bands at the SSCP and 2 showed faint PCR products most likely caused by the amplification of residual normal cells present in the analyzed samples. Figure 2 shows the results of exon 2 PCR-SSCP analysis in some representative cases.
I~nmu,lophenot~pic and genetic features ofp16 -/-ALLY. Table 2 shows the results of immunophenotypic. cytogenetic, and molecular characterization of ALL cases with p16 homozygous deletion. The techniques used for these studies had been reported elsewhere.''.'' Of the 8 patients with B-lineage ALL, 6 had a pre-pre B CALLA' phenotype (TdT'. HLN DR'. CD19', CDIO', Cyt.lg-) and 2 showed less differentiated early B features (TdT'. HLADR'. CD19'. Cyt.Ig-. CDIO-). The 2 other cases presented thymic T-cell features (see Table 2 ). These phenotypes did not show significant variation from the phenotypes observed in the whole ALL population analyzed in this study.
As to genetic analyses, 6 of 7 p16 -/-cases with available karyotype had nonrandom chromosome translocations (Table 2 ). In particular. a t(9;22) (q34;qI I ) was found in cases no. I , 3, and 9; a t(4; 1 1 ) (q21:q23) in cases no. 4 and 10; and complex numerical and structural changes including a t(8; 1 I ) (q13;plS) and a t(3:5) (q21:q31) were present in case no. 2. Molecular study of t(9: 22)-and t(4: 1 1 )-positive cases by reverse transcription-PCR (RT-PCR) with specific oligoprimers showed the presence in leukemic cells of the corresponding BCWABL and ALLlIAF4 hybrid fusion genes ( Table 2) .
Sequenticrlanal~sis ofp16 at diagnosisand rclrrpse. Diagnostic and relapse DNA specimens were available in 2 cases (nos. 4 and 7) with p16
In both cases. p16 homozygous loss was present either at diagnosis or at relapse. In patient no. 4, who had a t(4; 1 I ), DNA rearrangement of the ALL-I gene locus was detected together with p16 -/-in both samples (Fig 3 ) . 
Clinical feature's and treatment outcome of p16 -1-ALL.
Hematologic and clinical features at presentation and treatment outcome of the I O patients with p16 -/-are shown in Table 3 . Four patients had a white blood cell count (WBC) of greater than 100 X 1O"IL at presentation. Nine of 10 had massive tumor burden with lymph nodes. liver, and spleen involvement. Patient no.
5 presented with central nervous system (CNS) and orbital tumor masses in addition to hepato-splenomegaly and lymph nodes involvement. Four patients died of their disease for early relapse or resistant leukemia (cases no. I , 4. 7, and 10) and 1 patient (no. 8) died at I 1 days after bone marrow transplantation (BMT) because of pulmonary hemorrhage. Patient no. 6 presented with hyperleukocytosis and could not start treatment because of renal failure. Case no. S. which showed features of aggressive disease, underwent allogeneic BMT in first complete remis- Liver, spleen, and lymph nodes involvement.
t Liver, spleen, lymph nodes, CNS, and orbital (retro-ocular) tumor involvement.
* Studied at relapse.
For personal use only. on October 30, 2017. by guest www.bloodjournal.org From sion (CR) and is actually in CR 2 months after BMT. Finally, patients no. 2 and 3 are in first CR at 10 and 36 months, respectively, and patient no. 9, who was studied at relapse, is in second CR at 1 month after reinduction treatment. Chemotherapy protocols used in childhood and adult ALL have been reported elsewhere.2'.22
Comparison of prognostic features in p16 -/-and p16
+/+ ALL. The analysis of prognostically relevant parameters in ALL according to p16 gene status showed that patients with p16 homozygous deletion had significantly higher WBC counts and greater leukemic cell mass compared with p16 germline cases. No differences were found in the two groups with respect to age, sex, and immunophenotype (Table 4) . In the present study, we report homozygous deletions of p16 in a sizable fraction of ALL cases. By contrast, it appears from our PCR-SSCP analysis that this gene is rarely affected by point mutations in this leukemic subset and in non-Hodgkin's lymphoma. Given the difficulty of detecting hemizygous deletions in samples contaminated by variable fractions of normal cells, we did not perform this analysis in our study. On the other hand, the absence of point mutations in the tumors analyzed suggests that loss of one allele and inactivation of the other one by point mutation does not represent a common inactivation mechanism in this gene.
Because this series is retrospective and made up with stored DNAs, the hereby reported frequency of p16 deletion in ALL (17% of cases) might not reflect the exact incidence of such lesion in this tumor subset. However, our data are in agreement with the results recently published by Ogawa et al.' While confirming the findings of these investigators in ALL by analyzing a larger series of cases, we report here the absence of p16 -1-in other hematopoietic tumors and in myelodysplastic syndromes. Therefore, homozygous p16 deletions seem to be associated with a specific subset in hematologic neoplasia. Furthermore, we provide a preliminary biologic and clinical characterization of p16 -/-ALLs.
Seven cases had a karyotypic characterization. Of these, 5 showed alterations usually associated with ALL within acute leukemias, ie, t(9;22) and t(4; l l), and 1 showed a t (3;5) . This latter abnormality is mostly detected in myelodysplastic syndromes, therapy-related leukemia, and CML blast ~h r i s i s .~~*~' Notably, all of these genetic changes are associated with unfavorable prognosis.2G28
Clinical features at presentation such as hyperleukocytosis andor massive tumor burden were present in all but l (no.
3) p16 -/-case and correlated with poor clinical outcome. More significantly, we found a statistically significant association between high blood cell counts and leukemic mass in p16 4-ALL cases as compared with p16 +/+ ALLs (Table   4 ). Given the different population studied (adults and children) and the low number of patients receiving homogeneous therapy, a comparative analysis of treatment outcome in ALL according to p16 status was not possible in the present study. Several lines of evidence suggest that this alteration may have a role in ALL progression rather than in tumor initiation. In fact, in none of the 7 cases with available karyotype was the p16 -/-lesion detected as an isolated abnormality. Furthermore, t(9;22), t(4; 1 l), and t(3;5) are all known to be primary abnormalities with pathogenetic relevance,25 probably conferring to their target cells genomic instability and making them prone to acquire additional aberrations. In this context, it is noteworthy that, in the 2 cases here analyzed at diagnosis and at relapse, p16 deletion was already detectable at diagnosis, but the time elapsed between diagnosis and relapse was extremely short; this finding suggests that multiple genetic derangements of leukemic cells at diagnosis might have favored a very aggressive clinical course. In case no. 4, indeed, rearrangement of the ALL-l locus at llq23 and p16 homozygous deletion were seen at diagnosis and at relapse (Fig 2) ; relapse occurred at 2 months after first remission.
In conclusion, we provide here preliminary evidence that alterations in the p16 gene are detectable in a sizable fraction of ALL and correlate with adverse prognostic features in these patients. Further studies analyzing the impact of this lesion on survival in larger series of patients are needed to establish the clinical relevance of p16 deletion in ALL.
